Literature DB >> 28759026

Association between GvHD and nivolumab in the FDA adverse event reporting system.

Y Oshima1, T Tanimoto2, K Yuji1, A Tojo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28759026     DOI： 10.1038/bmt.2017.158

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  8 in total

Review 1.  Immune checkpoint blockade in hematologic malignancies.

Authors:  Philippe Armand
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

2.  Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.

Authors:  Reid W Merryman; Haesook T Kim; Pier Luigi Zinzani; Carmelo Carlo-Stella; Stephen M Ansell; Miguel-Angel Perales; Abraham Avigdor; Ahmad S Halwani; Roch Houot; Tony Marchand; Nathalie Dhedin; Willy Lescaut; Anne Thiebaut-Bertrand; Sylvie François; Aspasia Stamatoullas-Bastard; Pierre-Simon Rohrlich; Hélène Labussière Wallet; Luca Castagna; Armando Santoro; Veronika Bachanova; Scott C Bresler; Amitabh Srivastava; Harim Kim; Emily Pesek; Marie Chammas; Carol Reynolds; Vincent T Ho; Joseph H Antin; Jerome Ritz; Robert J Soiffer; Philippe Armand
Journal:  Blood       Date:  2017-01-10       Impact factor: 22.113

3.  Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation.

Authors:  L Angenendt; C Schliemann; M Lutz; E Rebber; A B Schulze; M Weckesser; L Stegger; M Schäfers; C Groth; T Kessler; G Lenz; M Stelljes; W E Berdel
Journal:  Bone Marrow Transplant       Date:  2015-11-09       Impact factor: 5.483

4.  Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.

Authors:  Charles Herbaux; Jordan Gauthier; Pauline Brice; Elodie Drumez; Loic Ysebaert; Hélène Doyen; Luc Fornecker; Krimo Bouabdallah; Guillaume Manson; Hervé Ghesquières; Reza Tabrizi; Eric Hermet; Julien Lazarovici; Anne Thiebaut-Bertrand; Adrien Chauchet; Hélène Demarquette; Eileen Boyle; Roch Houot; Ibrahim Yakoub-Agha; Franck Morschhauser
Journal:  Blood       Date:  2017-03-07       Impact factor: 22.113

Review 5.  Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma.

Authors:  Shigeo Fuji; Takero Shindo
Journal:  Stem Cell Investig       Date:  2016-10-31

6.  PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells.

Authors:  Xiong Ni; Qingxiao Song; Kaniel Cassady; Ruishu Deng; Hua Jin; Mingfeng Zhang; Haidong Dong; Stephen Forman; Paul J Martin; Yuan-Zhong Chen; Jianmin Wang; Defu Zeng
Journal:  J Clin Invest       Date:  2017-04-17       Impact factor: 14.808

7.  Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism.

Authors:  Bruce R Blazar; Beatriz M Carreno; Angela Panoskaltsis-Mortari; Laura Carter; Yoshiko Iwai; Hideo Yagita; Hiroyuki Nishimura; Patricia A Taylor
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

8.  Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.

Authors:  Asim Saha; Kazutoshi Aoyama; Patricia A Taylor; Brent H Koehn; Rachelle G Veenstra; Angela Panoskaltsis-Mortari; David H Munn; William J Murphy; Miyuki Azuma; Hideo Yagita; Brian T Fife; Mohammed H Sayegh; Nader Najafian; Gerard Socie; Rafi Ahmed; Gordon J Freeman; Arlene H Sharpe; Bruce R Blazar
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113
  8 in total
  4 in total

Review 1.  Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas.

Authors:  Silvana Novelli; Anna Monter; M Pilar García-Muret; Rodrigo Martino; Javier Briones; Jorge Sierra
Journal:  Int J Hematol       Date:  2019-07-17       Impact factor: 2.490

2.  Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation.

Authors:  Julie Charles; Diane Giovannini; Nicolas Terzi; Carole Schwebel; Nathalie Sturm; Dominique Masson; Marie-Thérèse Leccia; Jean-Yves Cahn; Olivier Manches; Claude-Eric Bulabois; Laurence Chaperot
Journal:  Exp Hematol Oncol       Date:  2019-03-28

3.  High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma.

Authors:  Ryszard Swoboda; Sebastian Giebel; Wanda Knopińska-Posłuszny; Ewa Chmielowska; Joanna Drozd-Sokołowska; Ewa Paszkiewicz-Kozik; Waldemar Kulikowski; Michał Taszner; Włodzimierz Mendrek; Jacek Najda; Tomasz Czerw; Magdalena Olszewska-Szopa; Anna Czyż; Agnieszka Giza; Wojciech Spychałowicz; Edyta Subocz; Paweł Szwedyk; Aleksandra Krzywon; Agata Wilk; Jan Maciej Zaucha
Journal:  Ann Hematol       Date:  2021-02-24       Impact factor: 3.673

4.  Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions.

Authors:  Kota Kurosaki; Yoshihiro Uesawa
Journal:  Biomolecules       Date:  2021-06-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.